Cardlytics Inc (NASDAQ:CDLX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Cardlytics Inc (NASDAQ:CDLX) have received a consensus rating of “Buy” from the nine analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $33.67.

A number of analysts have issued reports on CDLX shares. Zacks Investment Research lowered Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. SunTrust Banks raised their target price on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 9th. Bank of America reissued a “buy” rating and set a $32.00 price objective (up previously from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. ValuEngine lowered Cardlytics from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, William Blair started coverage on Cardlytics in a report on Monday, July 1st. They set an “outperform” rating on the stock.

In other Cardlytics news, CFO David Thomas Evans sold 1,500 shares of Cardlytics stock in a transaction on Monday, July 15th. The stock was sold at an average price of $28.14, for a total value of $42,210.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Lynne Marie Laube sold 1,460 shares of Cardlytics stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $31.91, for a total value of $46,588.60. The disclosure for this sale can be found here. Insiders have sold a total of 2,901,632 shares of company stock worth $90,132,576 in the last three months. 21.90% of the stock is owned by insiders.



Institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can raised its position in Cardlytics by 16,371.4% in the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Cardlytics in the 2nd quarter valued at $60,000. Rockefeller Capital Management L.P. bought a new position in Cardlytics in the 2nd quarter valued at $85,000. Acadian Asset Management LLC bought a new position in Cardlytics in the 2nd quarter valued at $161,000. Finally, Royal Bank of Canada raised its position in Cardlytics by 166.5% in the 2nd quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock valued at $276,000 after purchasing an additional 6,649 shares during the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

Shares of CDLX stock traded down $2.42 during trading on Thursday, reaching $33.37. The company had a trading volume of 559,289 shares, compared to its average volume of 305,127. The firm’s 50 day simple moving average is $34.43 and its two-hundred day simple moving average is $24.59. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.01 and a quick ratio of 2.01. Cardlytics has a one year low of $9.80 and a one year high of $39.62. The company has a market capitalization of $824.08 million, a PE ratio of -15.59 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.23. The firm had revenue of $48.73 million for the quarter, compared to analyst estimates of $43.77 million. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The company’s revenue was up 37.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.21) EPS. Analysts forecast that Cardlytics will post -1.08 earnings per share for the current year.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: Mutual Funds

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.